Wong Pierre C, Parimi Prabhu S, Domachowske Joseph B, Friedman Deborah M, Marcus Michael G, Garcia Daniel F, La Via William V, Syed Iqra A, Szabo Shelagh M, McLaurin Kimmie K, Kumar Veena R
Children's Hospital Los Angeles, Los Angeles, CA, USA.
University of Kansas Hospital, Kansas City, KS, USA.
Clin Pediatr (Phila). 2016 Nov;55(13):1230-1241. doi: 10.1177/0009922815621343. Epub 2016 Jan 8.
This study was conducted to survey US pediatric specialists about administration of respiratory syncytial virus (RSV) immunoprophylaxis, communication patterns among physicians and parents, and barriers to access. Separate surveys were sent to neonatologists, pediatricians, pediatric pulmonologists, and pediatric cardiologists. Most physicians (≥93.5%) routinely recommended immunoprophylaxis to high-risk children. Most respondents (≥71.8%) reported that >50.0% of eligible infants and young children received each monthly dose throughout the RSV season, with the first dose most commonly administered before discharge from the birth hospitalization. To ensure receipt of subsequent doses, specialists frequently scheduled a follow-up visit at the end of the current appointment. All specialists reported insurance denials as the biggest obstacle to the administration of immunoprophylaxis to high-risk children. These findings may be used to improve adherence to immunoprophylaxis by enhancing education and physician-parent communications about severe RSV disease prevention, and by reducing known barriers to use of this preventive therapy.
本研究旨在就呼吸道合胞病毒(RSV)免疫预防的应用、医生与家长之间的沟通模式以及获取障碍等问题,对美国儿科专家进行调查。分别向新生儿科医生、儿科医生、儿科肺科医生和儿科心脏病专家发送了调查问卷。大多数医生(≥93.5%)常规向高危儿童推荐免疫预防措施。大多数受访者(≥71.8%)报告称,在整个RSV流行季节,超过50.0%的符合条件的婴幼儿接受了每月的每剂药物治疗,首剂药物最常在出生住院出院前给药。为确保后续剂量的接种,专家们经常在当前预约结束时安排随访。所有专家都报告称,保险拒付是对高危儿童进行免疫预防的最大障碍。这些研究结果可用于通过加强关于预防严重RSV疾病的教育以及医生与家长之间的沟通,并减少已知的使用这种预防性治疗的障碍,来提高免疫预防的依从性。